| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (NCT02315196) | Rutgers, The State University of New Jersey | 2015-02-25 |
| MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer (NCT01805076) | Alliance for Clinical Trials in Oncology | 2014-05-21 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (NCT01881230) | Celgene | 2013-09-26 |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT01818063) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-04-25 |
| Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (NCT01372579) | Northwestern University | 2011-08-01 |
| Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery (NCT01234532) | University of Maryland, Baltimore | 2010-10-01 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer (NCT01104259) | University of Washington | 2010-07-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer (NCT01151449) | National Cancer Institute (NCI) | 2010-06-01 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (NCT01100489) | Case Comprehensive Cancer Center | 2010-02-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer (NCT00602043) | National Cancer Institute (NCI) | 2008-09-01 |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer (NCT00733408) | University of Washington | 2008-04-23 |
| Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery (NCT00559507) | National Cancer Institute (NCI) | 2007-10-01 |
| Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer (NCT00516243) | National Cancer Institute (NCI) | 2007-07-01 |
| Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer (NCT00577122) | Indiana University | 2007-07-01 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery (NCT00194779) | University of Washington | 2003-10-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer (NCT00003199) | Fred Hutchinson Cancer Center | 1997-11-01 |